Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic Intra-Arterial Ipilimumab + IV Nivolumab in Advanced HCC
NCT04823403Phase 1Recruiting
- Sponsor
- Gustave Roussy
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab in hepatocellular carcinoma (HCC), sponsored by Gustave Roussy. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Nov 2020; status: recruiting.
02
Drugs
ipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04823403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04823403.